|Home | About | Journals | Submit | Contact Us | Français|
To evaluate the effectiveness, safety and feasibility of percutaneous vertebroplasty in the treatment of spinal metastatic tumor.
Thirty-four patients with spinal metastatic tumor who received treatment in the First Affiliated Hospital of Zhengzhou University from May 2014 to June 2015 were selected. Totally fifty diseased vertebrae were treated by percutaneous vertebroplasty. The curative effects were evaluated according to visual analogue scale (VAS) score, Oswestry Dability Index (ODI) and dose of pain reliever. The leakage conditions of bone cement and clinical complications were observed. The patients were followed up for 3 to 12 months.
The average VAS score and ODI 24 h after treatment were much lower than those before treatment, and the difference had statistical significance (P<0.05). The average VAS score and ODI at different follow-up periods after treatment were not significantly different (P>0.05). During follow up, nine patients stopped taking pain reliever, the dose of 18 patients had obvious reduction, and 7 patients kept previous dose; the incidence of bone cement leakage was 38.25%. Six patients had fever after surgery, but recovered after expectant treatment; 2 patients felt uncomfortable in the right lower limbs, but relieved after expectant treatment.
Percutaneous vertebroplasty can relieve pain efficiently, improve the daily living ability, and significantly enhance the living quality of patients with spinal metastatic tumors, with small trauma and high safety.
Bone metastasis is frequently seen in the spinal, and its incidence is 5% to 10% among tumor patients. Its incidence in thoracic vertebra is the highest (70%), followed by lumbar vertebra (20%) and cervical vertebra (10%). Breast carcinoma, pulmonary carcinoma and prostatic cancer are the most common primary lesions for patients with bone metastasis tumors.1,2 Patients with spinal metastatic tumors usually have clinical manifestations such as intense pain, neurological disorders and paralysis, which brings huge pains for patients and also severely affects the living quality and survival period of patients.3
The current treatment approaches for spinal metastatic tumors include chemotherapy, radiotherapy and surgery.4 Radiotherapy is the most common therapy; but it cannot improve neurological function, especially spinal paralysis, by relieving spinal instability induced by tumors. Moreover, radiotherapy is ineffective for preventing advanced collapse of patients with pathological fracture. As the indication range of open decompression surgery is narrow, most patients who have spinal metastatic tumor or vertebral hemangioma in more than two segments often go untreated; moreover, patients with advanced tumors are difficult to tolerate open decompression surgery due to heavy trauma and multiple complications. Percutaneous vertebroplasty, a kind of minimally invasive spinal treatment technology, has been applied in the treatment of intractable pain in recent years and has achieved good effects.5,6 This study aims at observing the clinical effects of percutaneous vertebroplasty in the treatment of spinal metastatic tumors and evaluate safety, thus to provide a reference for the clinical treatment.
Thirty-four patients who received percutaneous vertebroplasty in the hospital from May 2014 to July 2015 were retrospectively analyzed. Totally fifty vertebrae were included, including 3 cervical vertebrae, 24 thoracic vertebrae and 4 sacral vertebrae. There were 23 males and 11 females, aged from 38 to 74 years old. There were 16 cases of liver carcinoma, 7 cases of pulmonary carcinoma, 4 cases of breast cancer, 5 cases of colorectal carcinoma and 2 cases of gastric carcinoma. The tumors of all patients have been pathologically diagnosed. Before surgery, the patients underwent thoracolumbar spine computed tomography (CT) or Magnetic Resonance Imaging (MRI); 20 patients were diagnosed as pathological fracture in vertebrae, 15 patients had bone cortex rupture at vertebral posterior border, and 5 patients had nerve root compression, among which, 2 patients had weakened limbs muscle force. All patients had intense pain induced by spinal metastatic tumors in different sites. Twenty-four patients orally took opium analgesics and 10 patients orally took nonopioids; their Visual Analogue Scale (VAS) scores became larger than 4 points after medication. The study has been approved by the ethics committee of the hospital. The patients have signed informed consent. Those who had surgical contraindication, mental diseases, or cardiac, hepatic and liver function abnormality were excluded.
11 G or 13 G Bone puncture needle (Shanghai Kinetic Medical Co. Ltd., China), bone guider (KMC, USA), bone cement (Tecres S. P. A. Company, Italy) and cardiovascular imaging system (GE medical Systems SCS, Germany) were used.
All the cases were discussed in the clinical departments before surgery. Appropriate operation plans were designed based on the clinical manifestations, injured segments and imaging characteristics. The doctors were invited from relevant departs for consultation to exclude patients with surgical contraindications. Thorough countermeasures were formulated for the difficulties and risks that might be encountered during operation.
The first step was the insertion of bone puncture needle. Patients took a prone position on a Digital Subtraction Angiography (DSA) table (cervical vertebra took a supine position). The diseased vertebrae and puncture point were determined under the guidance of DSA. Then the puncture channels were narcotized one by one. The puncture needle was inserted into the center of the vertebrae along the puncture paths simulated before surgery. After the confirmation by adem position perspective, the needle core was removed. Then a kirschner wire was inserted and the outer sleeve of the bone puncture needle was pulled out. The bone guider was inserted to the position which was 1/3 before vertebrae along the kirschner wire. The second step was the infusion of bone cement. Bone cement was infused into a bone cement cannula (1.5 ml). The cannula was pushed into the diseased vertebrae under the real-time monitoring when the bone cement became viscous. The injection stopped when the bone cement closed to the vertebra posterior border or severe complications happened. Antibiotics were used one hour before surgery and one day after surgery to prevent infection.
All patients completed percutaneous vertebroplasty under the guidance of DSA, and the success rate of surgery was 100%. The infusion amount of bone cement for each vertebra was 1~5 ml (average 3.22±0.84 ml), as shown in Fig.2. Of the 50 vertebrae, bone cement leaked out in 19 vertebrae (38.2%). The leakage of bone cement happened in paravertebral soft tissues (6 thoracic vertebrae and 4 lumbar vertebra), paravertebral veins (4 lumbar vertebrae), 4 intervertebral discs (2 thoracic vertebrae and 2 lumbar vertebrae) and canalis vertebralis (2 lumbar vertebrae). The leakage could be discovered under perspective during operation, and the infusion stopped immediately after leakage was observed.
The average VAS score and ODI values 24 h after surgery were much lower than those before surgery, and the differences had statistical significance (P<0.05). The average VAS score and ODI values at different follow-up periods after surgery had no significant differences (P>0.05) (Table-I).
After surgery, nine patients stopped medication, 18 patients took half of the previous dose, and seven patients kept the previous dose. 79.4% of patients (27/34) reduced the dose of pain reliever or did not take pain reliever anymore.
After surgery, six patients had fever, but recovered after expectant treatment; two patients felt uncomfortable in the right lower limbs, but also relieved after expectant treatment. Infection, bleeding and pulmonary embolism were not observed in all patients. Moreover, the second fracture of the surrounding vertebrae and diseased vertebrae were not observed.
Spinal metastatic tumors have a high incidence and death rate among bone metastatic tumors. It may result in the pathological fracture of vertebrae and compression of spinal cord and nerve root, besides pains in waist and back. Therefore, the stability of spine is required to be improved in the treatment of spinal metastatic tumors, besides the relief of pains.9,10 Though there are many clinical therapies for spinal metastatic tumors, they all have defects.
Percutaneous vertebroplasty means infusing biomaterials such as bone cement into vertebrae using minimally invasive technology. It can improve the compressive strength of diseased vertebrae, avoid the collapse and malformation of vertebrae, relieve pains, and enhance body functions. As reported, the remission rate of the method was 75% to 94%.11 However, the pain relief mechanism of the therapy has not been thoroughly known. But there are several possible action mechanisms.12-16 The first one is heat effect and toxic effect. The toxic effect and heat produced during the polymerization of polymethyl methacrylate lead to the necrosis of pain nerve endings or tumor tissues in vertebrae. The second is mechanical effect. The evenly distributed bone cement can play a function of mechanical support, which prevents the occurrence of small activities of vertebrae and pains. The last one is vascular effect. The infusion of bone cement induces the necrosis of pain nerve endings or tumor tissues in vertebrae by blocking the supporting veins of vertebrae. In this study, the success rate of surgery was relatively high and the VAS score and ODI values after surgery were significantly lower than those before surgery, indicating percutaneous vertebroplasty could significantly and rapidly relieve pains, which was consistent with the findings of Wang HW et al.11
In clinic, bone cement leakage is a commonly seen complication in percutaneous vertebroplasty, i.e., bone cement may leak to paravertebral soft tissues, canalis vertebralis, intervertebral disks and basivertebral veins. But there are no obvious symptoms in most cases. The incidence of bone cement leakage is 30% to 87.5%.17 But the complications associated to bone cement leakage are usually not severe. Gargin found that, the incidence of bone cement leakage was 4% and the incidence of spinal cord compression was 0.5% in percutaneous vertebroplasty.18 Surgery should be performed if corresponding symptoms and vital signs appear when the leaked bone cement oppresses nerve root or spinal cord. In this study, 15 patients had bone destruction in vertebra posterior border. Percutaneous vertebroplasty is effective for patients with bone destruction in vertebra posterior border, but it has high risks and the surgery should be operated by experienced doctors. Other complications include pulmonary embolism, secondary fracture of surrounding vertebrae, local and systemic infection and temporary fever and pain. For patients with metastatic tumors in vertebrae, percutaneous vertebroplasty can timely relieve pain and enhance function, and the effects can last to the end of follow up. In the long run, the therapy is also safe.
The incidence of complications was extremely low in this study, which might be correlated to the small sample size. The postoperative survival time analysis was not involved in the study. Therefore, it is difficult to evaluate the influence of percutaneous vertebroplasty on the prognosis of spinal metastasis tumor. Further studies with large sample size are needed.
Percutaneous vertebroplasty can improve the strength and stability of vertebrae, prevent further collapse of vertebrae, and relieve pain in waist and back. Moreover, the heat effect and toxic effect produced by polymethyl methacrylate can help kill tumor cells. Most patients can tolerate the surgery because of the small trauma, significant relief effect and few complications; it is a safe, effective and minimally invasive surgical method. But percutaneous vertebroplasty also has limitations in controlling spiral tumors. It can be combined with ordinary radiotherapy, radiofrequency ablation and radioactive seeds implantation. Tumor is a systemic disease; therefore, primary tumors should also be treated to extend the survival time of patients.
YLL & LMW: Study design, data collection and analysis.
YQW, LZ, RPS & LMW: Manuscript preparation, drafting and revising.
YLL & HYT: Review and final approval of manuscript.
Declaration of interest: All authors declared there was no conflict interests involved.
Grant Support & Financial Disclosures: None.